SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported net income of $27.9 million in its third quarter. On a per-share basis, the ...

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close on ...

CEO Raul Rodriguez highlighted, “For the third quarter, we reported total revenue of $69.5 million, including record net product sales of $64.1 million, a 65% year-over-year increase.” He noted that ...

Based on the one-year price targets offered by 6 analysts, the average target price for Rigel Pharmaceuticals Inc (NASDAQ:RIGL) is $38.33, with a high estimate of $67.00 and a low estimate of $23.00.

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.7 per share a year ago. These ...

Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug to Rigel Pharma in a deal ...